Haleon (NYSE:HLN - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.11 per share for the quarter.
Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The company had revenue of $3.50 billion during the quarter, compared to analysts' expectations of $3.55 billion. During the same period in the prior year, the firm earned $0.08 EPS. On average, analysts expect Haleon to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Haleon Price Performance
NYSE:HLN traded down $0.07 during midday trading on Tuesday, hitting $9.92. The company had a trading volume of 5,984,100 shares, compared to its average volume of 5,174,355. The company has a market capitalization of $45.27 billion, a PE ratio of 33.05, a P/E/G ratio of 2.90 and a beta of 0.26. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon has a 52-week low of $7.70 and a 52-week high of $10.80. The stock's fifty day moving average price is $10.24 and its 200-day moving average price is $9.23.
Haleon Cuts Dividend
The company also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio (DPR) is presently 33.33%.
Analyst Upgrades and Downgrades
HLN has been the subject of several research reports. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They issued a "buy" rating for the company. UBS Group raised shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. The Goldman Sachs Group lowered shares of Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. Finally, Morgan Stanley boosted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research note on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Haleon currently has an average rating of "Buy" and a consensus price target of $10.95.
Read Our Latest Stock Report on HLN
About Haleon
(
Get Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Read More
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
